News
What's happening in Alzheimer's care, research funding, and treatment — summarized simply, each item linked to the original reporting.
Free to read, “May need a subscription” and “Archived copy”: what they mean
Whether an article is free to read is a guess, not a test of your access. Each item is one of three:
- No label: free to read (304 of 349). The publisher’s page marks it free, or the outlet publishes free to read: Medical Xpress, ScienceDaily, NIH (incl. NIA and PMC), Alzheimer's Association, Alzheimer's News Today, NPR, Alzheimer's Disease International, or a .gov site.
- May need a subscription (11 of 349). The publisher’s own page marks the article as not free to read, or — when the page says nothing — the outlet sells subscriptions: The New York Times, STAT, Scientific American, The Washington Post, The Wall Street Journal, Financial Times, The Economist, Bloomberg, The Atlantic, The New Yorker, Wired, Los Angeles Times, The Boston Globe, The Times, The Telegraph, New Scientist, Endpoints News, Science. Each badge says which.
- “Free to read? Not known” (34 of 349). The outlet is on neither list and its page said nothing. We do not call these paywalled.
Archived copy links go to a copy the Internet Archive (web.archive.org) saved, dated the day it was saved. We show one only where the Internet Archive reported a working saved copy when we checked; an archived copy of a subscription article sometimes shows only its opening. 265 of 349 items have one.
Depression might signal brain disease risk among seniors
Depression in old age could be an early sign of serious brain disease, a new study says.
Why it matters: A new study indicates that depression in old age might be an early sign of serious brain disease.
New ALS treatment target identified: STAUFEN-1 protein reduction protects brain cells from death
University of Utah researchers at the Pulst-Scoles Laboratory have discovered that reducing levels of the STAUFEN-1 protein can prevent neuron death caused by DNA damage and p53 activation in neurodegenerative diseases.
Why it matters: Reducing STAUFEN-1 protein levels can prevent neuron death caused by DNA damage and p53 activation in neurodegenerative diseases like ALS.
Read at Medical Xpress →Massive brain study reveals why memory loss can suddenly speed up with age
A massive international brain study has revealed that memory decline with age isn’t driven by a single brain region or gene, but by widespread structural changes across the brain that build up over time. …
Read at ScienceDaily → Archived copy (23 Sep 2026), Internet ArchiveKey phospholipid points to potential treatment for vascular dementia
A possible new treatment for impaired brain blood flow and related dementias is on the horizon. Research by scientists at the University of Vermont Robert Larner…
Why it matters: Research by scientists at the University of Vermont Robert Larner points to a potential treatment for impaired brain blood flow and vascular dementia.
Read at Medical Xpress → Archived copy (3 Jan 2026), Internet ArchiveHidden 'switches' in DNA reveal new insights into Alzheimer's disease
A tiny percentage of our DNA—around 2%—contains 20,000-odd genes. The remaining 98%—long known as the non-coding genome, or so-called 'junk' DNA—includes many of the "switches" that control when and how strongly genes are expressed.
Read at Medical Xpress → Archived copy (17 Feb 2026), Internet ArchiveAlzheimer's disease more prevalent in older people than previously thought
New research, published in Nature, has provided the first ever population-based data on the frequency of Alzheimer's disease neuropathological changes (ADNC)—a key causal factor behind the development of dementia…
Why it matters: New research in Nature provides the first population-based data on Alzheimer's disease neuropathological changes, showing higher prevalence in older people than thought.
Engineers decode dementia type using AI and EEG brainwave analysis
Dementia is a group of disorders that gradually impair memory, thinking and daily functioning. Alzheimer's disease (AD), the most common form of dementia, affects about 7.2 million Americans aged 65 and older in 2025. …
Read at Medical Xpress → Archived copy (14 Feb 2026), Internet ArchiveMiddle-aged brains show capacity for repair when treated with therapeutic intervention
Normal aging is characterized by deficits in the cognitive domains of learning, memory and executive function. Specifically, there are age-related changes in recall of information, speed of processing, visuospatial skills and cognitive flexibility. …
Why it matters: Normal aging brings cognitive deficits in learning, memory, and executive function, but middle-aged brains demonstrate a capacity for repair when treated with therapeutic intervention.
Read at Medical Xpress → Archived copy (29 Dec 2025), Internet ArchivePill form of semaglutide fails to slow Alzheimer's in large trial
A pill version of semaglutide, the ingredient in Ozempic and Wegovy, did not slow the progress of Alzheimer's disease, drugmaker Novo Nordisk announced on Nov. 24.
Why it matters: A pill form of semaglutide failed to slow Alzheimer's disease progression in a large trial, Novo Nordisk announced on Nov. 24.
Read at Medical Xpress → Archived copy (6 Jan 2026), Internet ArchiveNovel discovery reveals how brain protein OTULIN controls tau expression and could transform Alzheimer's treatment
Scientists have uncovered a surprising mechanism by which a brain enzyme called OTULIN controls the expression of tau, the protein that forms toxic tangles in Alzheimer's disease. …
Why it matters: Scientists uncovered a surprising mechanism by which the brain enzyme OTULIN controls tau expression, which could transform Alzheimer's treatment.
Read at Medical Xpress → Archived copy (25 Nov 2025), Internet ArchiveAlzheimer's Association Statement on Oral Semaglutide Phase 3 Topline Data Release
Novo Nordisk's EVOKE and EVOKE+ Phase 3 trials of oral semaglutide in more than 3,800 people with early symptomatic Alzheimer's did not meet the primary endpoint of significantly slowing disease progression, despite improving some Alzheimer's-related biomarkers. Novo Nordisk ended its Alzheimer's trials for semaglutide, including the injectable version.
Why it matters: A high-profile failure for the theory that GLP-1 weight-loss drugs could treat Alzheimer's, dampening near-term hopes for repurposing this popular drug class for dementia.
Read at Alzheimer's Association → Archived copy (30 Jul 2026), Internet ArchiveJ&J's Novel Alzheimer's Drug Fails in Key Trial, Dimming Hopes for a Hot Target
Johnson & Johnson terminated its mid-stage trial of posdinemab, a tau-targeting antibody, after an early analysis showed it was not outperforming placebo in slowing Alzheimer's progression.
Why it matters: A setback for the broader strategy of targeting tau protein rather than amyloid, a drug class also being pursued by Biogen, UCB, and Voyager Therapeutics.
May need a subscription Based on the outlet (STAT), not a check of this article.
Read at STAT News → Archived copy (1 Mar 2026), Internet ArchiveAPOE gene raises delirium risk even without dementia, global analysis reveals
A major genetic risk factor for delirium has been identified in a study that analyzed the DNA of more than 1 million people worldwide.
Why it matters: A study analyzing DNA from over 1 million people worldwide identified a major genetic risk factor for delirium.
Genetic risk combined with cardiovascular factors may help predict and delay dementia
Combining genetic risk with cardiovascular disease risk factors—such as high LDL cholesterol, obesity, and hypertension—may predict who is more likely to develop dementia, according to a new study led by UC San Francisco.
Why it matters: Combining genetic risk with cardiovascular disease risk factors—such as high LDL cholesterol, obesity, and hypertension—may predict who is more likely to develop dementia.
Read at Medical Xpress → Archived copy (22 Jan 2026), Internet ArchiveSimple blood test may someday allow for diagnosis of LATE dementia during life
Jijing Wang, Ph.D., and Hyun-Sik Yang, MD, of the Department of Neurology at Mass General Brigham, are the lead and senior authors of a paper published in Molecular Neurodegeneration titled "Plasma TDP-43 is a potential biomarker for advanced limbic-predominant…
Why it matters: A simple blood test measuring plasma TDP-43 may someday enable doctors to diagnose advanced LATE dementia during a patient's life.
Read at Medical Xpress → Archived copy (21 Nov 2025), Internet ArchiveShingles vaccine most promising common drug to potentially prevent Alzheimer's
A new study has identified three existing medications that could be repurposed to treat or prevent Alzheimer's disease.
Why it matters: A new study identified three existing medications, including the shingles vaccine, that could be repurposed to treat or prevent Alzheimer's disease.
Read at Medical Xpress → Archived copy (19 Nov 2025), Internet ArchiveGene 'switch' reverses Alzheimer's risk in experimental model
University of Kentucky researchers have developed a new experimental model that could point the way toward more effective Alzheimer's disease treatments by targeting one of the brain's most important genes for risk and resilience.
Why it matters: Researchers have developed a new experimental model that could point the way toward more effective Alzheimer's disease treatments.
Just 3,000 steps a day linked to lower Alzheimer's risk in older adults
A new study suggests that even low levels of physical activity could protect the brain from Alzheimer's disease—but not in the way scientists expected.
Why it matters: A new study suggests that low levels of physical activity, like 3,000 steps a day, could protect the brain from Alzheimer's in unexpected ways.
Read at Medical Xpress → Archived copy (12 Nov 2025), Internet ArchiveProtective microglia subtype offers potential therapeutic pathway in Alzheimer's disease
In Alzheimer's disease—the leading cause of dementia—microglia, the brain's immune defenders, can act as both protectors and aggressors, shaping how the disease progresses.
Read at Medical Xpress → Archived copy (15 Nov 2025), Internet Archive5,000 Steps a Day Could Slow Cognitive Decline in People With Signs of Alzheimer's, Study Suggests
A Mass General Brigham-led observational study tracking nearly 300 older adults for up to 14 years found that low-to-moderate physical activity (benefits plateauing around 5,000-7,500 daily steps) was linked to about 50% slower cognitive decline in people with high baseline amyloid, and correlated with slower tau accumulation.
Why it matters: Reinforces exercise as an accessible, low-cost way to potentially delay decline in people already showing early Alzheimer's brain changes, though the observational design can't prove cause and effect.
May need a subscription Based on the outlet (STAT), not a check of this article.
Read at STAT News (study in Nature Medicine) → Archived copy (3 Mar 2026), Internet ArchiveU.S. POINTER Study Shows Structured Lifestyle Program Improves Cognition in Older Adults at Risk
The two-year U.S. POINTER trial of 2,111 older adults at five U.S. sites found that both a structured and a self-guided multidomain lifestyle intervention (diet, exercise, cognitive/social engagement, health monitoring) improved cognition, with the structured program producing significantly greater gains. Results were published simultaneously in JAMA.
Why it matters: First large U.S. randomized trial showing an accessible lifestyle program can protect cognition in a diverse at-risk population, offering a non-drug strategy alongside emerging medications.
Read at Alzheimer's Association / AAIC → Archived copy (6 Sep 2026), Internet ArchiveRoche Presents New Insights in Alzheimer's Disease Research at AAIC (Trontinemab Phase Ib/IIa Data)
Roche's trontinemab, an antibody engineered to cross the blood-brain barrier more efficiently, cleared amyloid below the positivity threshold in 91% of participants at the highest dose after 28 weeks, with ARIA-E occurring in fewer than 5% of participants. Roche plans Phase 3 trials (TRONTIER 1 and 2) starting later in 2025.
Why it matters: Suggests a next-generation amyloid antibody could clear plaques faster and with a better safety profile than currently approved drugs, if Phase 3 results confirm early findings.
Free to read? Not known for this outlet.
Read at Roche → Archived copy (25 Jul 2026), Internet ArchiveBiological clock based on blood measurements predicts mouse lifespan and frailty
NIA investigators have created a biological clock for mice based on blood measurements. Learn how the clock can help predict differences in aging and how the findings could translate to clinical practice.
Why it matters: NIA investigators created a biological clock for mice based on blood measurements that helps predict differences in aging and could translate to clinical practice.
Read at NIH National Institute on Aging → Archived copy (2 Aug 2026), Internet ArchiveNIA statement on the U.S. Cost of Dementia Model report
Read an announcement about an NIA-funded project that reports the economic burden of Alzheimer's disease and related dementia in the United States.
Why it matters: An NIA-funded project reports the economic burden of Alzheimer's disease and related dementia in the United States.
Read at NIH National Institute on Aging → Archived copy (2 Aug 2026), Internet ArchiveAlzheon's Alzheimer's Pill Fails in Phase III Trial
Alzheon's oral drug valiltramiprosate missed the primary endpoint in its 325-patient APOLLOE4 Phase 3 trial of early Alzheimer's patients with two copies of the APOE4 gene, though a prespecified mild cognitive impairment subgroup showed larger cognitive and functional benefits.
Why it matters: Another setback for a non-antibody, oral approach to Alzheimer's treatment, though the positive subgroup signal could still support a narrower regulatory path.
Free to read? Not known for this outlet.
Read at Clinical Trials Arena → Archived copy (17 Jun 2026), Internet ArchiveA gene guiding brain cell growth may regulate Alzheimer’s plaque size and toxicity
Plexin-B1 shapes glial networks around beta-amyloid plaques. An NIA-funded study has found that targeting it may improve plaque clearance and reduce brain inflammation.
Why it matters: Targeting Plexin-B1 may improve beta-amyloid plaque clearance and reduce brain inflammation, offering a potential path to regulate Alzheimer's plaque size and toxicity.
Read at NIH National Institute on Aging → Archived copy (2 Oct 2026), Internet ArchiveNew drug candidate targeting synaptic resilience well tolerated in Alzheimer’s patients
A new drug targeting synaptic resilience shows potential in treating Alzheimer’s disease in an NIA-funded study, with early trials indicating safety and possible brain damage reduction. Further research is needed on the drug’s long-term effects.
Why it matters: An NIA-funded study shows a new Alzheimer's drug candidate targeting synaptic resilience is well tolerated in early trials and may reduce brain damage.
South Africa cash transfer program slowed cognitive decline for midlife and older adults
A modest cash-transfer intervention slowed memory decline and lowered dementia risk among midlife and older adults in rural South Africa.
Why it matters: A modest cash-transfer intervention slowed memory decline and lowered dementia risk among midlife and older adults in rural South Africa.
Read at NIH National Institute on Aging → Archived copy (30 Jul 2026), Internet ArchiveReview of Medicare data reveals potential new statistics on dementia diagnosis
A study of Medicare data showed that roughly 9% of beneficiaries — 5.3 million people — may have Alzheimer’s disease or a related dementia.
Why it matters: A review of Medicare data indicates that approximately 9 percent of beneficiaries, totaling 5.3 million people, may have Alzheimer’s disease or a related dementia.
Risk and future burden of dementia in the United States
NIA study reveals that nearly 42% of Americans over 55 may develop dementia, with new cases possibly doubling by 2060. Learn about the rising risk and future impact.
Why it matters: An NIA study reveals that nearly 42% of Americans over 55 may develop dementia, with new cases possibly doubling by 2060.
Follow new items in a feed reader: Atom feed.